A new kind of antibody targets a feature shared by proteins thought to cause the most damage in Alzheimer’s disease, Parkinson’s disease, and related conditions, creating potential for a unified treatment approach.
This is the finding of a study led by researchers from NYU School of Medicine and published online August 29 in Scientific Reports.
The new study is based on decades of work arguing that the contribution to disease of key proteins—amyloid beta and tau in Alzheimer’s disease, alpha-synuclein in Parkinson’s disease, and prion proteins in conditions like mad cow disease—is driven by certain, toxic forms dominated by a common structure: bundles of “beta sheets” in clumped proteins.
In tissues from autopsied patients with these diseases and in live mice, experiments demonstrated how the study antibodies target and remove only these toxic forms, say the authors, and without triggering the immune toxicity that has frustrated treatment development efforts to date.
“In an atmosphere where countless treatments have failed in clinical trials over the last 15 years, the fact that our approach continues to be effective in rigorous tests should be of interest to our peers and the industry, even if it runs contrary to conventional thinking,” says corresponding author Fernando Goni, PhD, research associate professor in the Department of Neurology at NYU Langone Health.
“While we still have a number of milestones to reach before this work is ready for clinical testing, our results suggest that these antibodies may halt key pathological mechanisms across several neurological diseases and regardless of disease stage,” says corresponding author Thomas Wisniewski, MD, director of NYU Langone’s Center for Cognitive Neurology, Silberstein Alzheimer’s Institute, and Alzheimer’s Disease Center.
New Approach to Antibody Design
The study focuses on proteins that form important structures in the brain. The instant they form as chains of amino acids, proteins fold into complex shapes needed to do their jobs. Unfortunately, proteins can also “misfold” for countless reasons, such as genetic abnormalities, toxins, age-associated cell processes, and inflammation that eventually cause the diseases addressed by the current study. Cells and tissues die as misshapen proteins stop working and build up, but the field has struggled to pinpoint which of these shifting forms to target as the key drivers of disease.
Many research efforts, including the current study, seek to design antibodies shaped to attach to and remove the right targets. Past and ongoing attempts have targeted the initial, short chains of amino acids that serve as basic, repeating structural units, or monomers, of each misfolded protein. Still others targeted end-stage fibrils, each made of thousands of monomers, which accumulate in plaques and tangles that tissues cannot eliminate. Neither approach has yielded an effective therapy.
In that light, Dr. Goni, Dr. Wisniewski, and colleagues designed their antibodies to target instead the “oligomers” formed as several misfolded monomers associate and acquire the “beta-sheet” shape, but before they are large enough to fibrilize. These intermediate forms may be uniquely toxic, say many in the field, because, unlike fibrils, they can dissolve, move in and out of cells, and from one cell to another. This mobility may explain the “prion-like” progression seen in misfolding diseases where abnormal proteins cause normal ones to misfold in a domino effect that damages nerve cells and their connections in the brain.
Importantly, growing toxic oligomers of amyloid beta, tau, alpha synuclein, and prion protein become increasingly dominated by the twisted strands of amino acids called beta sheets, which have spatial arrangements that let the strands stack up.
To design new kinds of antibodies, the research team zeroed in on a small 13-amino acid peptide, derived from the extremely rare genetic disease called British amyloidosis, but not present in the rest of the human population. They converted it into a larger, stable oligomer with more than 90 percent “beta-sheet” structure—the p13Bri immunogen—that could be “seen” by the mammalian immune system, and that could trigger a specific antibody response to solve problems encountered with standard approaches. By immunizing mice with p13Bri at high doses, they forced the production of extremely rare antibodies against beta sheets in toxic oligomers.
The researchers say that their rare antibodies, activated by a protein fragment seen only in a rare disease, have almost zero chance of triggering unwanted immune responses to normal proteins with similar sequences (autotoxicity), the downfall of many previous attempts. Finally, the team screened their lead antibodies against tissues taken from the brains of human patients with Alzheimer’s disease, Parkinson’s disease, and prion diseases. Only the six monoclonal antibodies that reacted to toxic oligomers from at least two misfolded proteins from two diseases were selected for further study.
“This publication details the first system for making antibodies that truly target only toxic oligomers of misfolded proteins dominated by beta sheets across several diseases, and without regard to the amino acid makeup of each misfolded protein’s monomer,” says Dr. Goni.
The Latest on: Neurological diseases
- Are occasionally shaky hands a sign of Parkinson's disease?on August 1, 2022 at 7:10 am
DPA If your hands sometimes shake, should you be worried it's a sign of Parkinson's disease? Not necessarily, as hand tremors can have many causes. Laura Ludwig/dpa . Trembling ...
- Ex-Putin advisor Anatoly Chubais suddenly sick from rare neurological disorderon July 31, 2022 at 7:12 pm
Anatoly Chubais was suffering from a neurological disorder at a European hospital, according to Ksenia Sobchak, a Russian television personality and friend of Chubais. Sobchak, on Telegram, spoke with ...
- Common Viruses May Be Triggering Alzheimer’s Diseaseon July 31, 2022 at 2:28 am
Shingles infection may awaken dormant neurological herpes viruses, causing inflammation and accumulation of Alzheimer’s associated proteins in the brain. Alzheimer’s disease is the most common cause ...
- Bill Gates, Jeff Bezos Unite To 'Change The Course' Of Neurological Disorder Impacting 6.5 Million Americanson July 30, 2022 at 1:04 pm
It’s a well-known fact that Microsoft Corporation (NASDAQ: MSFT) co-founder Bill Gates, through his Bill & Melinda Gates Foundation, is working toward eliminating infectious diseases and eradicating ...
- UAE: Hospital Saves Life Of 12-Year-Old Boy Suffering From Rare Neurological Diseaseon July 30, 2022 at 12:54 pm
Doctors at a private hospital in Sharjah saved a 12-year-old boy's life from a rare neurological disorder that left him paralysed and with respiratory failure. Son of Indian expatriates Praveen and ...
- Biogen’s New Drug Application for first treatment of rare form of neurological disease accepted by FDAon July 28, 2022 at 5:58 am
A drug to target a rare genetic form of a neurological disease that affects the nerve cells could be the first if approved.
- Following nature's rules, researchers develop new methods for treating degenerative neurological diseaseon July 27, 2022 at 4:45 am
University of Arizona researchers have developed a new class of drugs that is able to cross the blood-brain barrier and could be used to treat degenerative neurological diseases and conditions.
- Can a baby’s cry identify neurological disorders? Ubenwa says ‘yes’on July 25, 2022 at 6:00 pm
When Charles Onu’s cousin was born with birth asphyxia and later developed a hearing condition, the seed for Ubenwa, an audio biometric company geared at identifying neurological disorders in infants, ...
- How sickle cell disease affects neurological conditionson July 13, 2022 at 2:10 pm
Hyacinth I. Hyacinth, PhD, MBBS, studies racial health disparities in neurological conditions at the University of Cincinnati and is currently leading two research projects to learn more about the ...
- How sickle cell disease affects neurological conditionson July 13, 2022 at 10:30 am
Sickle cell disease (SCD), a blood disorder that primarily affects people of African ancestry, can cause a variety of symptoms in patients, including stroke and cognitive impairment. Hyacinth I.
via Google News and Bing News